Journal articles on the topic 'Lytic induction therapy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Lytic induction therapy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Yiu, Stephanie Pei Tung, Mike Dorothea, Kwai Fung Hui, and Alan Kwok Shing Chiang. "Lytic Induction Therapy against Epstein–Barr Virus-Associated Malignancies: Past, Present, and Future." Cancers 12, no. 8 (August 2, 2020): 2142. http://dx.doi.org/10.3390/cancers12082142.
Full textFeng, Wen-hai, Gregory Hong, Henri-Jacques Delecluse, and Shannon C. Kenney. "Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas." Journal of Virology 78, no. 4 (February 15, 2004): 1893–902. http://dx.doi.org/10.1128/jvi.78.4.1893-1902.2004.
Full textDaibata, Masanori, Kentaro Bandobashi, Masayuki Kuroda, Shosuke Imai, Isao Miyoshi, and Hirokuni Taguchi. "Induction of Lytic Epstein-Barr Virus (EBV) Infection by Synergistic Action of Rituximab and Dexamethasone Renders EBV-Positive Lymphoma Cells More Susceptible to Ganciclovir Cytotoxicity In Vitro and In Vivo." Journal of Virology 79, no. 9 (May 1, 2005): 5875–79. http://dx.doi.org/10.1128/jvi.79.9.5875-5879.2005.
Full textKorsak, Dorota, Sylvia Liebscher, and Waldemar Vollmer. "Susceptibility to Antibiotics and β-Lactamase Induction in Murein Hydrolase Mutants of Escherichia coli." Antimicrobial Agents and Chemotherapy 49, no. 4 (April 2005): 1404–9. http://dx.doi.org/10.1128/aac.49.4.1404-1409.2005.
Full textYiu, Stephanie Pei Tung, Kwai Fung Hui, Christian Münz, Kwok-Wai Lo, Sai Wah Tsao, Richard Yi Tsun Kao, Dan Yang, and Alan Kwok Shing Chiang. "Autophagy-Dependent Reactivation of Epstein-Barr Virus Lytic Cycle and Combinatorial Effects of Autophagy-Dependent and Independent Lytic Inducers in Nasopharyngeal Carcinoma." Cancers 11, no. 12 (November 26, 2019): 1871. http://dx.doi.org/10.3390/cancers11121871.
Full textTanner, JE, and J. Menezes. "Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease." Blood 84, no. 11 (December 1, 1994): 3956–64. http://dx.doi.org/10.1182/blood.v84.11.3956.bloodjournal84113956.
Full textLechowicz, Mary Jo, Jeannette Lee, Dirk Dittmer, Susan Krown, Jonathan Said, and Richard F. Ambinder. "A Pilot Trial of Valproic Acid in Patients with Kaposi’s Sarcoma: A Multi-Center Trial of the AIDS Malignancy Consortium." Blood 110, no. 11 (November 16, 2007): 2279. http://dx.doi.org/10.1182/blood.v110.11.2279.2279.
Full textCoileoni, Marco, Anna Maria Bochicchio, Franco Nolè, and Emilio Bajetta. "Disodium Pamidronate in the Treatment of Bone Metastases from Breast Cancer." Tumori Journal 79, no. 5 (October 1993): 340–42. http://dx.doi.org/10.1177/030089169307900511.
Full textHoward-Varona, Cristina, Dean Vik, Natalie Solonenko, Yueh-Fen Li, M. Gazitua, Lauren Chittick, Jennifer Samiec, et al. "Fighting Fire with Fire: Phage Potential for the Treatment of E. coli O157 Infection." Antibiotics 7, no. 4 (November 16, 2018): 101. http://dx.doi.org/10.3390/antibiotics7040101.
Full textScott, Emma, and Donna Reece. "What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?" Hematology 2011, no. 1 (December 10, 2011): 205–7. http://dx.doi.org/10.1182/asheducation-2011.1.205.
Full textLakshminarasimhan, Anirudha. "Prophage induction therapy: Activation of the lytic phase in prophages for the elimination of pathogenic bacteria." Medical Hypotheses 169 (December 2022): 110980. http://dx.doi.org/10.1016/j.mehy.2022.110980.
Full textGhobrial, Irene M., and A. Keith Stewart. "ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?" Hematology 2009, no. 1 (January 1, 2009): 587–89. http://dx.doi.org/10.1182/asheducation-2009.1.587.
Full textClayman, Gary L., Howard E. Savage, Gregory Young, Pierre Lavedan, Dorothy L. Taylor, and Stimson P. Schantz. "Detection of Regulatory Factors of Lymphokine-Activated Killer Cell Activity in Head and Neck Cancer Patients Treated with Interleukin-2 and Interferon Alpha." Annals of Otology, Rhinology & Laryngology 101, no. 11 (November 1992): 909–15. http://dx.doi.org/10.1177/000348949210101105.
Full textCleeland, Charles S., Xin Shelley Wang, Sheeba K. Thomas, Ping Liu, Mary H. Sailors, Tito R. Mendoza, James M. Reuben, et al. "Predictive value of baseline serum MIP-1α and CRP on symptom burden and tumor response to induction therapy in patients with multiple myeloma." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 8091. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8091.
Full textFaller, Douglas V., Sajal K. Ghosh, Susan P. Perrine, Robert M. Williams, and Ronald J. Berenson. "Histone Deacetylase Inhibitors: Potent Inducers of Tumor Latent EBV Thymidine Kinase Induction." Blood 116, no. 21 (November 19, 2010): 1831. http://dx.doi.org/10.1182/blood.v116.21.1831.1831.
Full textSankaranarayanan, N., K. Alleman, K. Charpentier, M. Brown, A. Lally, M. Lawlor, B. Cooper, D. Hull, and K. V. Ranga. "CYTOMEGALOVIRUS IMMUNE GLOBULIN (Ig) ALONE DOES NOT PREVENT SEROCONVERSION IN CMV MISMATCHED KIDNEY TRANSPLANT RECIPIENTS RECEIVING NON-LYTIC INDUCTION THERAPY." Transplantation 78 (July 2004): 483. http://dx.doi.org/10.1097/00007890-200407271-01299.
Full textFeng, Wen-hai, Eva Westphal, Amy Mauser, Nancy Raab-Traub, Margaret L. Gulley, Pierre Busson, and Shannon C. Kenney. "Use of Adenovirus Vectors Expressing Epstein-Barr Virus (EBV) Immediate-Early Protein BZLF1 or BRLF1 To Treat EBV-Positive Tumors." Journal of Virology 76, no. 21 (November 1, 2002): 10951–59. http://dx.doi.org/10.1128/jvi.76.21.10951-10959.2002.
Full textLotzová, E., C. A. Savary, and R. B. Herberman. "Induction of NK cell activity against fresh human leukemia in culture with interleukin 2." Journal of Immunology 138, no. 8 (April 15, 1987): 2718–27. http://dx.doi.org/10.4049/jimmunol.138.8.2718.
Full textDi Filippo, Michela Di, Paulina Hennig, Tugay Karakaya, Marta Slaufova, and Hans-Dietmar Beer. "NLRP1 in Cutaneous SCCs: An Example of the Complex Roles of Inflammasomes in Cancer Development." International Journal of Molecular Sciences 23, no. 20 (October 14, 2022): 12308. http://dx.doi.org/10.3390/ijms232012308.
Full textTazawa, Hiroshi, Joe Hasei, Shuya Yano, Shunsuke Kagawa, Toshifumi Ozaki, and Toshiyoshi Fujiwara. "Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy." Cancers 12, no. 2 (February 18, 2020): 478. http://dx.doi.org/10.3390/cancers12020478.
Full textBhatt, Shruti, Brittany Ashlock, Ngoc Toomey, Enrique Mesri, Juan Carlos Ramos, and Izidore S. Lossos. "Synergistic Preclinical Activity of Bortezomib with Suberoylanilide Hydroxamic Acid (SAHA) in Primary Effusion Lymphoma (PEL)." Blood 118, no. 21 (November 18, 2011): 1650. http://dx.doi.org/10.1182/blood.v118.21.1650.1650.
Full textNalbandyan, Karen, Daniel Benharroch, Benzion Samueli, Michael Kafka, and Anna Gourevitch. "Multiple Myeloma with Foamy Mott Cells." Case Reports in Hematology 2021 (August 10, 2021): 1–4. http://dx.doi.org/10.1155/2021/7391895.
Full textRaza, Shahzad, Rachael A. Safyan, Evan Rosenbaum, Alex S. Bowman, and Suzanne Lentzsch. "Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist." Therapeutic Advances in Hematology 8, no. 2 (December 9, 2016): 55–70. http://dx.doi.org/10.1177/2040620716680548.
Full textFaller, Douglas V., Sajal Ghosh, Tatyana Feldman, Adam Lerner, Judith Smith, Andre Goy, Ronald Berenson, and Susan Perrine. "Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas." Blood 114, no. 22 (November 20, 2009): 4754. http://dx.doi.org/10.1182/blood.v114.22.4754.4754.
Full textMoore, Stacy M., Jennifer S. Cannon, Yvette C. Tanhehco, Fayez M. Hamzeh, and Richard F. Ambinder. "Induction of Epstein-Barr Virus Kinases To Sensitize Tumor Cells to Nucleoside Analogues." Antimicrobial Agents and Chemotherapy 45, no. 7 (July 1, 2001): 2082–91. http://dx.doi.org/10.1128/aac.45.7.2082-2091.2001.
Full textChapoval, Andrei I., Jane A. Fuller, Sergey G. Kremlev, Sonya J. Kamdar, and Robert Evans. "Combination Chemotherapy and IL-15 Administration Induce Permanent Tumor Regression in a Mouse Lung Tumor Model: NK and T Cell-Mediated Effects Antagonized by B Cells." Journal of Immunology 161, no. 12 (December 15, 1998): 6977–84. http://dx.doi.org/10.4049/jimmunol.161.12.6977.
Full textDrayson, Mark, Gulnaz Begum, Supratik Basu, Sudhaker Makkuni, Janet Dunn, Nicola Barth, and J. Anthony Child. "Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials." Blood 108, no. 6 (September 15, 2006): 2013–19. http://dx.doi.org/10.1182/blood-2006-03-008953.
Full textStevens, Servi J. C., Christian M. Zwaan, Sandra A. W. M. Verkuijlen, and Jaap M. Middeldorp. "Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy." Head & Neck 28, no. 11 (2006): 1040–45. http://dx.doi.org/10.1002/hed.20466.
Full textArnason, Jon E., and Lourdes M. Mendez. "Induction Therapy for Gamma-Heavy Chain Disease with Bortezomib and Dexamethasone: A Case Report." Blood 120, no. 21 (November 16, 2012): 5051. http://dx.doi.org/10.1182/blood.v120.21.5051.5051.
Full textDugan, James, Bradley M. Haverkos, Ludmila Katherine Martin, Marisa F. Martin, Mark E. Lustberg, John T. Patton, Gerard Nuovo, et al. "Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder." Blood 124, no. 21 (December 6, 2014): 1750. http://dx.doi.org/10.1182/blood.v124.21.1750.1750.
Full textChatterjee, Anushila, Julia L. E. Willett, Gary M. Dunny, and Breck A. Duerkop. "Phage infection and sub-lethal antibiotic exposure mediate Enterococcus faecalis type VII secretion system dependent inhibition of bystander bacteria." PLOS Genetics 17, no. 1 (January 7, 2021): e1009204. http://dx.doi.org/10.1371/journal.pgen.1009204.
Full textFu, D., J. Chong, C. Foss, J. Fox, S. Wang, G. Green, J. Chen, M. V. Lemas, M. Pomper, and R. Ambinder. "Imaging and therapy for Epstein-Barr virus-associated gastric cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 4644. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4644.
Full textSauer, Sandra, Andreas Marco Fischer, Andrea Fraenzle, Christina Kunz, Maximilian Merz, Patrick Wuchter, Martina Schmaus, Anthony D. Ho, Hartmut Goldschmidt, and Jens Hillengass. "Impact of Radiation Therapy on Stem Cell Harvest in Multiple Myeloma." Blood 124, no. 21 (December 6, 2014): 5822. http://dx.doi.org/10.1182/blood.v124.21.5822.5822.
Full textHattori, Yutaka, Shin-ichiro Okamoto, Wenlin Du, Taketo Yamada, Naoki Shimada, Kunio Matsumoto, Morihiko Sagawa, and Yasuo Ikeda. "Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy." Blood 112, no. 11 (November 16, 2008): 1717. http://dx.doi.org/10.1182/blood.v112.11.1717.1717.
Full textShah, Gunjan L., Meier Hsu, Sean Devlin, David J. Chung, Hani Hassoun, Guenther Koehne, Neha S. Korde, et al. "Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents." Blood 126, no. 23 (December 3, 2015): 1996. http://dx.doi.org/10.1182/blood.v126.23.1996.1996.
Full textKeruakous, Amany, Silas Day, Azra Borogovac, Jennifer L. Holter, Adam Steven Asch, and Carrie Yuen. "Predictors of response to upfront bortezomib, lenalidomide and dexamethasone (VRd) in multiple myeloma." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e20507-e20507. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e20507.
Full textMohan, Meera, Rohan Samant, Larry J. Suva, Corey O. Montgomery, Daisy V. Alapat, Roy Morello, Frits van Rhee, et al. "Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience." Blood 126, no. 23 (December 3, 2015): 4193. http://dx.doi.org/10.1182/blood.v126.23.4193.4193.
Full textYan, Wenqiang, Huishou Fan, Jingyu Xu, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, and Gang An. "Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)." Blood 138, Supplement 1 (November 5, 2021): 3765. http://dx.doi.org/10.1182/blood-2021-149464.
Full textBiran, Noa, Vesna Najfeld, Emily Bagiella, Sundar Jagannath, and Ajai Chari. "Patients with Newly Diagnosed Multiple Myeloma and a Gain of the Long Arms of Chromosome 1 Have Inferior Outcomes, Including Early Onset Extramedullary Disease, Despite the Use of Novel Triplet Regimens." Blood 120, no. 21 (November 16, 2012): 4996. http://dx.doi.org/10.1182/blood.v120.21.4996.4996.
Full textEleutherakis Papaiakovou, Evangelos, Evangelos Terpos, Nikolaos Kanellias, Magdalini Migkou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, et al. "Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation." Blood 138, Supplement 1 (November 5, 2021): 3886. http://dx.doi.org/10.1182/blood-2021-149499.
Full textBagal, Bhausaheb, Hasmukh Jain, Uma Dangi, Manju Sengar, Sadhana Kannan, Venkatesh Rangarajan, Hari Menon, and Navin Khattry. "Pretransplant PET Positivity Predicts Early Relapse with Poor Outcome in Patients of Multiple Myeloma Undergoing Autologous Stem Cell Transplantation." Blood 124, no. 21 (December 6, 2014): 3997. http://dx.doi.org/10.1182/blood.v124.21.3997.3997.
Full textKorde, Neha S., Dickran Kazandjian, Mark Roschewski, Sham Mailankody, Malin Hultcrantz, Constance M. Yuan, Maryalice Stetler-Stevenson, et al. "Longitudinal 18f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R)." Blood 128, no. 22 (December 2, 2016): 3274. http://dx.doi.org/10.1182/blood.v128.22.3274.3274.
Full textBarillé-Nion, Sophie, Bart Barlogie, Régis Bataille, P. Leif Bergsagel, Joshua Epstein, Robert G. Fenton, Joth Jacobson, W. Michael Kuehl, John Shaughnessy, and Guido Tricot. "Advances in Biology and Therapy of Multiple Myeloma." Hematology 2003, no. 1 (January 1, 2003): 248–78. http://dx.doi.org/10.1182/asheducation-2003.1.248.
Full textGirnius, Saulius Kazmiems, Habte Aragaw Yimer, Sudhir Manda, Christopher A. Yasenchak, Veena Charu, Roger M. Lyons, Suman Kambhampati, et al. "Long-term proteasome inhibition in US community multiple myeloma (MM) patients (pts) following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib (I): Updated real-world (RW) data from US MM-6." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19332-e19332. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19332.
Full textMartin, Ludmila Katherine, Mark E. Lustberg, Fengting Yan, John T. Patton, Pierluigi Porcu, Gerard Nuovo, Robert Cavaliere, and Robert A. Baiocchi. "Successful Treatment of Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PCNS-PTLD) with Zidovudine (AZT), Ganciclovir (GCV), Rituximab and Dexamethasone: A Single-Institution Case Series." Blood 118, no. 21 (November 18, 2011): 3067. http://dx.doi.org/10.1182/blood.v118.21.3067.3067.
Full textBayraktar, Ulas D., Roberto Ochoa, Soley Bayraktar, Maria Matsangou, and Juan Carlos Ramos. "High-Dose Methotrexate and Azidothymidine in Combination with Alternating DA-EPOCH Is An Effective Regimen for the Treatment of EBV-Related Plasmablastic Lymphoma." Blood 114, no. 22 (November 20, 2009): 4753. http://dx.doi.org/10.1182/blood.v114.22.4753.4753.
Full textBaltathakis, Ioannis, Evangelos Terpos, Sosana Delimpasi, Konstantinos Liapis, Fotios Panitsas, Efstathios Kastritis, Anna Christoforidou, et al. "The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study." Blood 116, no. 21 (November 19, 2010): 3052. http://dx.doi.org/10.1182/blood.v116.21.3052.3052.
Full textRosiñol, Laura, Raquel Jiménez-Segura, Ana Isabel Teruel, Javier De La Rubia, Maria Victoria Mateos, Miguel T. Hernandez, Dolores Hernández, et al. "Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM)." Blood 122, no. 21 (November 15, 2013): 3188. http://dx.doi.org/10.1182/blood.v122.21.3188.3188.
Full textHill, Elizabeth, Neha Korde, Candis Morrison, Alexander Dew, Ashley Carpenter, Monica Epstein, Crystal Lu, et al. "The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)." Blood 136, Supplement 1 (November 5, 2020): 11–12. http://dx.doi.org/10.1182/blood-2020-136182.
Full textZuccolotto, G., A. Penna, IM Montagner, D. Carpanese, and A. Rosato. "P06.09 Anti-hPSMA CAR engineered NK-92 cells: An off-the-shelf cellular therapeutic for targeted elimination of prostate cancer cells." Journal for ImmunoTherapy of Cancer 8, Suppl 2 (October 2020): A45.1—A45. http://dx.doi.org/10.1136/jitc-2020-itoc7.88.
Full text